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ABSTRACT 
The defining feature of cancer cachexia is extensive weight loss and skeletal muscle atrophy. It is clinically 
important because cachexia reduces patient survival, results in functional impairment, and is estimated to 
be directly responsible for 20-40% of cancer deaths. Unfortunately, no clinical therapy exists and therefore, 
it is important to understand the molecular mechanisms responsible for rapid muscle wasting. Compared 
to limb muscles, the diaphragm is relatively understudied in cancer cachexia, but is likely to be adversely 
affected because cachexia is a systemic disease. Wasting of the primary inspiratory muscle may result in 
difficulty breathing and inability to adjust minute ventilation in response to a respiratory challenge. Based 
on emerging evidence, it is clear that oxidative stress is present in cachexia-induced wasting of the 
diaphragm; we developed the hypothesis that mitochondrial dysfunction in the diaphragm precedes 
cachexia. METHODS: 1X106 Lewis Lung Carcinoma cells (LLC) or Phosphate-Buffered Saline (PBS, 
control) were implanted to the hind-flank of C57BL6/J mice at 8 wks of age. Tumors were allowed to 
develop for 1, 2, 3, or 4 wks. At designated time points diaphragms were collected and mitochondrial 
function was assessed by respiration and ROS production. RESULTS: Cancer cachexia was evident only at 
the 4 wk time point demonstrated by decrease in body mass and muscle atrophy in several limb muscles. 
Mitochondrial respiration, assessed by respiratory control ratio (state3/state 4 respiration), was 
significantly lower at 1 wk (p<0.05) post-implantation and stayed depressed. ROS production was 
significantly elevated early in the time course (2 wk time point) compared to control (p<0.05), however 
wks 3 and 4 were not different from control. CONCLUSIONS: The molecular events that lead to muscle 
atrophy in cancer cachexia are unknown. We demonstrate that two hallmarks of mitochondrial 
dysfunction, altered respiration and ROS production, occur in the diaphragm well before the cancer 
cachexia phenotype is evident in the LLC model. These data suggest that the mitochondria are likely a 
suitable target to treat or prevent cancer cachexia-induced muscle wasting in the diaphragm.   
